Barry brings 20 years of experience in executive management and leadership positions to Elm Street Ventures. Most recently, Barry served as Chief Executive Officer of Glygenix Therapeutics, Inc., a Connecticut-based gene therapy company developing treatments for a group of orphan diseases in children. He was also Principal of BLS Partners LLC, a management consulting firm. Before starting BLS Partners in 2014, Barry was an R&D and business leader in one of the world’s largest life sciences companies, Life Technologies Inc. He has also been a serial entrepreneur, helping to start up two biotechnology companies that were spun out of Yale University, including Molecular Staging Inc., which he joined in 1998 as Director of R&D, and then Protometrix, Inc., where he was the Senior Director of Technology when it was acquired by Invitrogen Corporation in 2004. Prior to entering the biotechnology sector, Barry was an Assistant Professor in the Department of Chemistry at the University of Central Florida. Before moving to Florida, he was a Leukemia Society Special Fellow in the Department of Pediatrics at Yale University School of Medicine, and a post-doctoral fellow at the Memorial Sloan-Kettering Cancer Institute. Barry received his Bachelor’s degree from Dartmouth College and his Ph.D. in Pharmacology from Yale University.